Source: http://www.google.com/patents/US7842674?dq=7125605
Timestamp: 2015-04-27 21:07:19
Document Index: 757697702

Matched Legal Cases: ['Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 553987', 'Application No. 2007116168', 'Application No. 00914455', 'Application No. 0702035']

Patent US7842674 - administering to a surgery patient in whom p53 protein is elevated as a ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and...http://www.google.com/patents/US7842674?utm_source=gb-gplus-sharePatent US7842674 - administering to a surgery patient in whom p53 protein is elevated as a result of a stress, a modified double stranded siRNA to down-regulate p53 in the patientAdvanced Patent SearchPublication numberUS7842674 B2Publication typeGrantApplication numberUS 11/827,199Publication dateNov 30, 2010Filing dateJul 10, 2007Priority dateSep 28, 2004Fee statusPaidAlso published asCA2580126A1, CA2580126C, CN102643818A, CN102643818B, EP1799269A2, EP1799269A4, US8148342, US8765699, US20060069056, US20080287382, US20090082291, US20120184597, WO2006035434A2, WO2006035434A3Publication number11827199, 827199, US 7842674 B2, US 7842674B2, US-B2-7842674, US7842674 B2, US7842674B2InventorsElena Feinstein, Shai EhrlichOriginal AssigneeQuark Pharmaceuticals Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (30), Non-Patent Citations (81), Referenced by (8), Classifications (11), Legal Events (4) External Links: USPTO, USPTO Assignment, Espacenetadministering to a surgery patient in whom p53 protein is elevated as a result of a stress, a modified double stranded siRNA to down-regulate p53 in the patient US 7842674 B2Abstract
wherein each of a, c, u, and g is an unmodified or a 2′�O-Me sugar-modified ribonucleotide and each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond; and
wherein alternating ribonucleotides in both the antisense and sense strands are modified in their sugar residues such that a 2′�O-Me group is present and modified sugar residues are present at the 5′ and 3′ termini of the antisense strand and unmodified sugar residues are present at the 5′ and 3′ termini of the sense strand, and
Thus, RNA interference (RNAi) refers to the process of sequence-specific post-transcriptional gene silencing in mammals mediated by small interfering RNAs (siRNAs) (Fire et al, 1998, Nature 391, 806) or microRNAs (miRNAs) (Ambros V. Nature 431:7006, 350-355 (2004); and Bartel D P. Cell. 2004 Jan. 23; 116(2): 281-97 MicroRNAs: genomics, biogenesis, mechanism, and function). The corresponding process in plants is commonly referred to as specific post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. An siRNA is a double-stranded RNA molecule which down-regulates or silences (prevents) the expression of a gene/mRNA of its endogenous (cellular) counterpart. RNA interference is based on the ability of dsRNA species to enter a specific protein complex, where it is then targeted to the complementary cellular RNA and specifically degrades it. Thus, the RNA interference response features an endonuclease complex containing an siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having a sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA may take place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al 2001, Genes Dev., 15, 188). In more detail, longer dsRNAs are digested into short (17-29 bp) dsRNA fragments (also referred to as short inhibitory RNAs��siRNAs�) by type III RNAses (DICER, DROSHA, etc., Bernstein et al., Nature, 2001, v. 409, p. 363-6; Lee et al., Nature, 2003, 425, p. 415-9). The RISC protein complex recognizes these fragments and complementary mRNA. The whole process is culminated by endonuclease cleavage of target mRNA (McManus&Sharp, Nature Rev Genet, 2002, v.3, p. 737-47; Paddison &Hannon, Curr Opin Mol Ther. 2003 June; 5(3): 217-24). For information on these terms and proposed mechanisms, see Bernstein E., Denli A M. Hannon G J: 2001 The rest is silence. RNA. I; 7(11): 1509-21; Nishikura K.: 2001 A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell. I 16; 107(4): 415-8 and PCT publication WO 01/36646 (Glover et al).
The human p53 gene is a well-known and highly studied gene. The p53 polypeptide plays a key role in cellular stress response mechanisms by converting a variety of different stimuli, for example DNA damaging conditions, such as gamma-irradiation, deregulation of transcription or replication, and oncogene transformation, into cell growth arrest or apoptosis (Gottlieb et al, 1996, Biochem. Biophys. Acta, 1287, p. 77). The p53 polypeptide is essential for the induction of programmed cell death or �apoptosis� as a response to such stimuli. Most anti-cancer therapies damage or kill also normal cells that contain native p53, causing severe side effects associated with the damage or death of healthy cells. Since such side effects are to a great extent determined by p53-mediated death of normal cells, the temporary suppression of p53 during the acute phase of anti-cancer therapy has been suggested as a therapeutic strategy to avoid these severe toxic events. This was described in U.S. Pat. No. 6,593,353 and in Komarov P G et al, 1999, A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy., Science, 285(5434):1651, 1653. p53 has been shown to be involved in chemotherapy and radiation-induced alopecia. (Botcharev et al, 2000, p53 is essential for Chemotherapy-induced Hair Loss, Cancer Research, 60, 5002-5006).
FIG. 1. This figure represents the nucleotide sequence of the human p53 gene�SEQ ID NO:1.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4497817Apr 26, 1983Feb 5, 1985Yamanouchi Pharmaceutical Co., Ltd.Antiallergens-immunosuppressive agentsUS5898031Jun 6, 1996Apr 27, 1999Isis Pharmaceuticals, Inc.Oligoribonucleotides for cleaving RNAUS6107094Jun 6, 1997Aug 22, 2000Isis Pharmaceuticals, Inc.In vitro modification of target rna by contacting solution of target and ribonuclease preferential for double-stranded rna with oligonucleotide complementary to target and including nucleotides modified to improve affinity/specificityUS6372249Oct 24, 1994Apr 16, 2002Baylor College Of MedicineSenscent cell-derived inhibitors of DNA synthesisUS6506559Dec 18, 1998Jan 14, 2003Carnegie Institute Of WashingtonMolecular hybridization of complementary strandsUS6593353Jan 28, 2000Jul 15, 2003Board Of Trustees Of The University Of Illinoisp53 inhibitors and therapeutic use of the sameUS6982277Jan 24, 2003Jan 3, 2006The Board Of Trutees Of The University Of IllinoisAntitumor agents, antiinflammatory agents; for example 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-yl)-1-(4-methylphenyl) -1-ethanone, 2-(4-methylphenyl)-5,6,7,8-tetrahydrobenzo(d)-imidazo(2,1-b)thiazoleUS7008956Jan 28, 2003Mar 7, 2006The Board Of Trustees Of The University Of Illinoisp53 inhibitors and therapeutic use of the sameUS7012087Jun 13, 2001Mar 14, 2006The Board Of Trustees Of The University Of IllinoisAnticancer agentsUS20020019425Sep 6, 2001Feb 14, 2002The Board Of Trustees Of The University Of IllinoisAnticancer agents; administering p53 gene or proteinUS20040014956Feb 3, 2003Jan 22, 2004Sequitur, Inc.For increasing nuclease resistance of antisense sequencesUS20040180351Aug 5, 2003Sep 16, 2004Atugen AgInterfering RNA moleculesUS20040209832Sep 23, 2003Oct 21, 2004Mcswiggen JamesRNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)US20050080246Jun 3, 2004Apr 14, 2005Charles AllersonCompositions comprising alternating 2'-modified nucleosides for use in gene modulationUS20060021739Aug 2, 2004Feb 2, 2006Young David PMethod and system for evaluating fluid flow through a heat exchangerUS20060069056Sep 27, 2005Mar 30, 2006Elena FeinsteinOligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesUS20060217329Aug 16, 2005Sep 28, 2006Elena FeinsteinTherapeutic uses of inhibitors of RTP801US20070031844Nov 14, 2003Feb 8, 2007Anastasia KhvorovaFunctional and hyperfunctional siRNAUS20070185047Dec 1, 2006Aug 9, 2007Balkrishen BhatDouble strand compositions comprising differentially modified strands for use in gene modulationUS20100048425Sep 18, 2009Feb 25, 2010Dharmacon, Inc.siRNA targeting tumor protein 53 (P53)EP0430334A1Nov 15, 1990Jun 5, 1991Janssen Pharmaceutica N.V.Immunostimulating 6-aryl-5,6-dihydroimidazo[2,1-b]thiazole derivativesWO2000044895A1Jan 29, 2000Aug 3, 2000Roland KreutzerMethod and medicament for inhibiting the expression of a defined geneWO2001036646A1Nov 17, 2000May 25, 2001Cancer Res Campaign TechInhibiting gene expression with dsrnaWO2001075164A2Mar 30, 2001Oct 11, 2001Whitehead Biomedical InstRna sequence-specific mediators of rna interferenceWO2002044321A2Nov 29, 2001Jun 6, 2002Max Planck GesellschaftRna interference mediating small rna moleculesWO2002055693A2Jan 9, 2002Jul 18, 2002Ribopharma AgMethod for inhibiting the expression of a target geneWO2003070918A2Feb 20, 2003Aug 28, 2003Ribozyme Pharm IncRna interference by modified short interfering nucleic acidWO2003074654A2Feb 20, 2003Sep 12, 2003Leonid BeigelmanRna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)WO2004015107A2Aug 5, 2003Feb 19, 2004Atugen AgFurther novel forms of interfering rna moleculesWO2006035434A2Sep 27, 2005Apr 6, 2006Quark Biotech IncOligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesNon-Patent CitationsReference1Amarzguioui M et al. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31(2):589-95.2Andrei Gudkov et al., U.S. Appl. No. 11/136,231, filed May 24, 2005.3Barik, Sailen (2005). "Silence of the Transcripts; RNA Interference In Medicine," J. Mol. Med. 83:764-773.4Bartel, D.P., (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116:281-297.5Bernstein, E., et al., (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.6Bitko, Vira et al. (2004). "Inhibition of Respiratory Viruses By Nasally Administered siRNA," Nature Medicine, 11(1):50-55.7Botchkarev, V.A., et al., (2000) p53 Is Essential for Chemotherapy-induced Hair Loss. Cancer Res. 60:5002-5006.8Brummelkamp, T.R., et al., (2002) A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. Science 296:550-553.9Caplen, N.J., et al., (2001) Specific inhibition of gene expression by small-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98(17):9742-9747.10Chakraborty, Chiranjib (2007) "Potentiality of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing," Current Drug Targets, 8:469-482.11Chalk, A.M., et al., (2004) Improved and automated prediction of effective siRNA. Biochem. Biophys. Res. Commun. 319:264-274.12Chernov, M.V. and Stark, G.R., (1997) The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 14:2503-2510.13Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Aug. 19, 2004 in connection with European Patent Application No. 00914455.1.14Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Feb. 12, 2004 in connection with European Patent Application No. 00914455.1.15Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Mar. 10, 2006 in connection with European Patent Application No. 00914455.1.16Communication pursuant to Article 96(2)EPC issued by the European Patent Office on May 13, 2005 in connection with European Patent Application No. 00914455.1.17Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Oct. 24, 2006 in connection with European Patent Application No. 00914455.1.18Communication under Rule 112 EPC issued by the European Patent Office on Dec. 16, 2003 in connection with European Patent Application No. 00914455.1.19Cotsarelis, G. and Millar, S.E., (2001) Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7(7):293-301.20Czauderna F, et al. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31(11):2705-16.21Elbashir SM et al. (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20(23):6877-88.22Elbashir, S.M., et al., (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.23Elbashir, S.M., et al., (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188-200.24Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008.25Examination Report issued by the Australian Patent Office on Dec. 22, 2008 in connection with New Zealand Patent Application No. 553987.26Final Office Action issued on Aug. 19, 2009 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.27Final Office Action issued on Dec. 3, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.28Fire, A., et al., (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.29Gottlieb, T.M., et al., (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102.30International Preliminary Report on Patentability issued by WIPO on Apr. 2, 2009 in connection with International Application No. PCT/IL2005/001035.31International Search Report issued by the International Searching Authority (ISA/US) on Dec. 3, 2007 in connection with International Application No. PCT/IL05/01035.32Komarov, P.G., et al., (1999) A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy. Science 285:1733-1737.33Komarova, E.A., et al., (1997) Transgenic mice with p53-responsive IacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16(6):1391-1400.34Lee, Youngtae et al., (2003). "The nuclear RNase III Drosha initiates mircoRNA processing," Nature, 425:415-419.35Levenkova, N., et al., (2004) Gene specific siRNA selector. Bloinformatics 20 (3):430-432.36McManus, M.T. and Sharp, P.A., (2002) Gene Silencing in Mammals by Small Interfering RNAs. Nature Rev. Genet. 3:737-747.37Molitoris, BA et al. (2009) "siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury", JASN Express, 20: 1754-1764.38Notice of Allowance mailed on Apr. 7, 2009 in connection with Elena Feinstein et al., U.S. Appl. No. 11/655,610, filed Jan. 18, 2007.39Notice of Allowance mailed on Nov. 18, 2009 in connection with Elena Feinstein et al., U.S. Appl. No. 11/237,598, filed Sep. 27, 2005, and allowed claims.40Office Action issued by the Russian Patent Office on Jul. 20, 2009 in connection with Russian Patent Application No. 2007116168.41Office Action issued on Apr. 21, 2005 in connection with U.S. Appl. No. 10/352,597, filed Jan. 28, 2003.42Office Action issued on Apr. 6, 2004 in connection with U.S. Appl. No. 10/350,560, filed Jan. 24, 2003.43Office Action issued on Dec. 28, 2001 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.44Office Action issued on Feb. 12, 2003 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.45Office Action issued on Jan. 3, 2005 in connection with U.S. Appl. No. 10/350,560, filed Jan. 24, 2003.46Office Action issued on Jul. 13, 2004 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.47Office Action issued on Jul. 15, 2001 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.48Office Action issued on Jul. 2, 2001 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.49Office Action issued on Jul. 9, 2004 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.50Office Action issued on Jun. 6, 2002 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.51Office Action issued on Mar. 14, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.52Office Action issued on Mar. 23, 2001 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.53Office Action issued on Mar. 26, 2003 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.54Office Action issued on May 1, 2008 in connection with U.S. Appl. No. 11/655,610, filed Jan. 18, 2007.55Office Action issued on Nov. 19, 2003 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.56Office Action issued on Nov. 26, 2004 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.57Office Action issued on Nov. 9, 2006 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.58Office Action issued on Oct. 2, 2008 in connection with U.S. Appl. No. 11/655,610, filed Jan. 18, 2007.59Office Action issued on Oct. 28, 2008 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.60Office Action issued on Oct. 30, 2007 in connection with U.S. Appl. No. 11/136,231, filed May 24, 2005.61Office Action issued on Oct. 9, 2003 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.62Office Action issued on Sep. 9, 2004 in connection with U.S. Appl. No. 10/352,597, filed Jan. 28, 2003.63Pending claims in Elena Feinstein et al., U.S. Appl. No. 12/008,578, filed Jul. 11, 2008.64Pending claims in Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008.65Pending claims in U.S. Appl. No. 11/136,231, filed May 24, 2005.66Prakash TP et al. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48(13):4247-53.67Result of consultation issued by the European Patent Office on Oct. 25, 2005 in connection with European Patent Application No. 00914455.1.68Search Report issued by the Australian Patent Office on May 14, 2008 in connection with Singaporean Application/Patent No. 0702035-7.69Second Written Opinion issued by the Australian Patent Office on May 26, 2009 in connection with Singaporean Application No. 0702035-7.70Sioud, M. and Leirdal, M., (2004) Potential design rules and enzymatic synthesis of siRNAs. Methods Mol. Biol. 252:457-469.71Steele, R.J.C., et al., (1998) The p53 tumour suppressor gene. Br. J. Surg. 85:1460-1467.72Supavekin, S., et al., (2003) Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 63:1714-1724.73TeKippe, M., et al., (2003) Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp. Hematol. 31:521-527.74Tolentino, M.J., et al., (2004) Intravitreal Injection of Vascular Endothelial Growth Factor Small Interfering RNA Inhibits Growth and Leakage in a Nonhuman Primate, Laser-Induced Model of Choroidal Neovascularization. Retina 24:132-138.75Ui-Tei, K., et al., (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32(3):936-948.76Wang, J. et al., (2003). "A Peptide Inhibitor of c-Jun N-Terminal Kinase Protects against . . . ," The J. of Neuroscience, 23(24):8596-8607.77Wlodarski, P., et al., (1998) Role of p53 in Hematopoietic Recovery After Cytotoxic Treatment. Blood 91(8):2998-3006.78Written Opinion issued by the Australian Patent Office on May 14, 2008 in connection with Singaporean Application/Patent No. 0702035-7.79Written Opinion of the International Searching Authority (ISA/US) issued on Dec. 3, 2007 in connection with International Application No. PCT/IL05/01035.80Zhang, M. et al., (2003). "Pifithrin-alpha Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis," Neuroscience, 120:191-205.81Zhang, M. et al., (2003). "Pifithrin-α Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis," Neuroscience, 120:191-205.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS8148342Jan 11, 2008Apr 3, 2012Quark Pharmaceuticals Inc.Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesUS8404654Jul 1, 2009Mar 26, 2013Quark Pharmaceuticals, Inc.Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesUS8637482Jun 7, 2010Jan 28, 2014Quark Pharmaceuticals, Inc.Methods for treating chronic kidney diseaseUS8742091Jun 20, 2002Jun 3, 2014Dainippon Sumitomo Pharma Co., Ltd.Method of promoting nucleic acid transferUS8765699Sep 27, 2005Jul 1, 2014Quark Pharmaceuticals, Inc.Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesUS8785408Jun 26, 2008Jul 22, 2014Quark Pharmaceuticals, Inc.Compositions and methods for reducing or protecting against delayed graft function (DGF)US20090258933 *Jun 17, 2009Oct 15, 2009Dainippon Pharmaceutical Co., Ltd.Oligonucleotides-transferring preparationsWO2014043292A1Sep 12, 2013Mar 20, 2014Quark Pharmaceuticals, Inc.Double-stranded oligonucleotide molecules to p53 and methods of use thereof* Cited by examinerClassifications U.S. Classification514/44.00R, 536/24.5, 536/23.1International ClassificationA61K31/70, C07H21/04Cooperative ClassificationC12N15/1135, C07H21/02, C12N2310/14, C12N15/113European ClassificationC12N15/113B, C07H21/02Legal EventsDateCodeEventDescriptionJun 3, 2014CCCertificate of correctionMay 23, 2014FPAYFee paymentYear of fee payment: 4Apr 19, 2011CCCertificate of correctionDec 3, 2007ASAssignmentOwner name: QUARK PHARMACUTICALS, INC.,CALIFORNIAFree format text: CHANGE OF NAME;ASSIGNOR:QUARK BIOTECH, INC.;US-ASSIGNMENT DATABASE UPDATED:20100427;REEL/FRAME:20206/703Effective date: 20070601Free format text: CHANGE OF NAME;ASSIGNOR:QUARK BIOTECH, INC.;REEL/FRAME:20206/703Owner name: QUARK PHARMACUTICALS, INC., CALIFORNIAFree format text: CHANGE OF NAME;ASSIGNOR:QUARK BIOTECH, INC.;REEL/FRAME:020206/0703Free format text: CHANGE OF NAME;ASSIGNOR:QUARK BIOTECH, INC.;REEL/FRAME:020206/0703RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services